Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2026-02-09 @ 5:01 AM
Study NCT ID:
NCT07087860
Status:
RECRUITING
Last Update Posted:
2025-12-09
First Post:
2025-07-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Sponsor:
Mayo Clinic
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Bladder Urothelial Carcinoma | View |
| None | Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | View |
| None | Refractory Bladder Urothelial Carcinoma | View |
| None | Refractory Renal Pelvis and Ureter Urothelial Carcinoma | View |
| None | Stage IV Bladder Cancer AJCC v7 | View |
| None | Stage IV Renal Pelvis and Ureter Cancer AJCC v7 | View |
Keywords: